The Diabetes Prevention Program: Baseline Characteristics of the Randomized Cohort. The Diabetes Prevention Program Research Group
Overview
Affiliations
Objective: The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes.
Research Design And Methods: Eligibility requirements were age > or = 25 years, BMI > or = 24 kg/m2 (> or = 22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or < or = 6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups--intensive lifestyle modification, standard care plus metformin, and standard care plus placebo--are presented for the 3,234 participants who have been randomized.
Results: Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 +/- 10.7 years (mean +/- SD), and 67.7% were women. Moreover, 16% were < 40 years of age, and 20% were > or = 60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 +/- 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI > or = 30 kg/m2. Average fasting plasma glucose (6.0 +/- 0.5 mmol/l) and HbA1c (5.9 +/- 0.5%) in men were comparable with values in women (5.9 +/- 0.4 mmol/l and 5.9 +/- 0.5%, respectively).
Conclusions: The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.
Fayaz S, Hamajima N, Frozanfar M, Hamrah M, Inthaphatha S, Nishino K Nagoya J Med Sci. 2025; 86(4):564-577.
PMID: 39780927 PMC: 11704768. DOI: 10.18999/nagjms.86.4.564.
Long-term impact of Diabetes Prevention Program interventions on walking endurance.
Munshi M, Venditti E, Tjaden A, Knowler W, Boyko E, Middelbeek R Front Public Health. 2025; 12():1470035.
PMID: 39744353 PMC: 11688401. DOI: 10.3389/fpubh.2024.1470035.
LeBlanc E, Smith N, Hwang D, Young D, Oshiro C, Mayhew M Contemp Clin Trials. 2024; 149:107796.
PMID: 39730078 PMC: 11788072. DOI: 10.1016/j.cct.2024.107796.
Allison K, McCuen-Wurst C, Raevsky A, Holmes N, Goldbach M, Guerra C Obes Sci Pract. 2024; 10(6):e70023.
PMID: 39713088 PMC: 11662970. DOI: 10.1002/osp4.70023.
Liu Y, De Jesus E, Goldbach M, Krouse R, Guerra C, Rendle K Support Care Cancer. 2024; 32(12):808.
PMID: 39567374 PMC: 11579159. DOI: 10.1007/s00520-024-08999-x.